MCF Advisors’s AtriCure ATRC Stock Holding History

MCF Advisors’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-387	Closed	-$17K	–	924
2023 Q3	$17K	Buy	+387	New	+$18.9K	﹤0.01%	508

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

MCF Advisors's ATRC Position: Q4 2023 in Review

MCF Advisors sold out of AtriCure (ATRC) in Q4 2023, closing a stake of 387 shares — an estimated $17K sold.

MCF Advisors first reported a position in ATRC in Q3 2023 and held it in 1 quarter. The position peaked at $17K in Q3 2023. 233 funds tracked by Wall St. Rank hold ATRC as of Q4 2023.

MCF Advisors reported no remaining AtriCure position as of Q4 2023 after selling out during the quarter.
MCF Advisors sold 387 AtriCure shares in Q4 2023, an estimated $17K.
MCF Advisors first reported a position in AtriCure in Q3 2023 and held it in 1 quarter.
MCF Advisors's AtriCure position peaked at $17K in Q3 2023.
233 funds tracked by Wall St. Rank held AtriCure as of Q4 2023.

Based on MCF Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.